Prosecution Insights
Last updated: April 19, 2026

Examiner: STEPHENS, AMELIA CAROLE

Tech Center 1600 • Art Units: 1645 1675

This examiner grants 0% of resolved cases

Performance Statistics

%
Allow Rate
-60.0% vs TC avg
15
Total Applications
+0.0%
Interview Lift
1175
Avg Prosecution Days
Based on 1 resolved cases, 2023–2026

Rejection Statute Breakdown

10.7%
§101 Eligibility
25.0%
§102 Novelty
14.3%
§103 Obviousness
28.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18519225 COMBINED USE OF UBENIMEX AND IMMUNE CHECKPOINT INHIBITOR Non-Final OA NIPPON KAYAKU KABUSHIKI KAISHA
18400897 TRANSKETOLASE EPITOPES, METHODS, AND DEVICES FOR IGG-BASED TUBERCULOSIS SERODIAGNOSIS Non-Final OA Wayne State University
18397180 VACCINATION AGAINST FUNGAL EPITOPES TO PREVENT INFLAMMATORY BOWEL DISEASES Non-Final OA THE UNIVERSITY OF UTAH
18573574 YEAST FOR THE TREATMENT OF INFLAMMATION Non-Final OA Milmed Unico AB
18570867 Bacteria and Herbal Extract Nutraceutical Blends for Lung Health Maintenance Non-Final OA RESBIOTIC NUTRITION, INC.
18268844 CONSTRUCTS COMPRISING SINGLE DOMAIN VHH ANTIBODIES AGAINST SARS COV-2 Non-Final OA Lumen Bioscience, Inc.
18265405 ANTI-EGFR CHIMERIC ANTIGEN RECEPTORS Non-Final OA Seattle Children's Hospital (dba Seattle Children's Research Institute)
18002591 CD-3 ANTIBODIES FOR THE TREATMENT OF CORONAVIRUS Non-Final OA Tiziana Life Sciences PLC
18032491 Methods of using passive immunity to decrease transmission of infectious diseases Non-Final OA CAMAS INCORPORATED
18248238 METHOD FOR TREATING OX40 RELATED DISEASE Non-Final OA Kyowa Kirin Co., Ltd.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month